Pulse Biosciences (PLSE) EBITDA (2015 - 2025)

Pulse Biosciences' EBITDA history runs 11 years deep, the most recent figure standing at -$19.4 million for Q3 2025.

• In Q3 2025, EBITDA fell 52.88% year-over-year to -$19.4 million; the TTM figure through Sep 2025 stood at -$74.7 million (down 61.99% YoY), while the FY2025 annual figure was $72.8 million, up 235.86% from the prior year.
• EBITDA was -$19.4 million for Q3 2025 at Pulse Biosciences, down from -$19.2 million in the prior quarter.
• In the past five years, EBITDA ranged from a high of -$9.2 million in Q4 2022 to a low of -$19.4 million in Q4 2024.
• Historically, EBITDA has averaged -$14.4 million across 5 years, with a median of -$14.3 million in 2021.
• The sharpest annual moves came in 2023 and 2025: EBITDA jumped 43.26% in 2023, then plunged 68.39% in 2025.
• A 5-year view of EBITDA shows it stood at -$15.4 million in 2021, then surged by 40.34% to -$9.2 million in 2022, then retreated by 29.75% to -$11.9 million in 2023, then plunged by 62.45% to -$19.4 million in 2024, then changed by 0.0% to -$19.4 million in 2025.
• The last three EBITDA figures came in at -$19.4 million (Q3 2025), -$19.2 million (Q2 2025), and -$16.8 million (Q1 2025), per Business Quant data.